Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Peripheral Nervous System Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Cardiotoxicity 1

Interventions

Cyclophosphamide 3155Cisplatin 3151Carboplatin 2929Paclitaxel 2671Radiotherapy 2643Gemcitabine 2544pembrolizumab 2324Docetaxel 2154Bevacizumab 2126Fluorouracil 1819Capecitabine 1780Oxaliplatin 1709Dexamethasone 1589Nivolumab 1516Doxorubicin 1477Rituximab 1453Etoposide 1341Magnetic Resonance Spectroscopy 1261Irinotecan 1232Leucovorin 1212Cytarabine 1123Pemetrexed 1060Drug Therapy 1060fludarabine 1044Vincristine 956Specimen Handling 928Prednisone 924Cetuximab 919Lenalidomide 916Trastuzumab 897

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Trimetazidine × Clear all
NCT06459193 2025-03-30

Trimetazidine Efficacy in Attenuating Paclitaxel-Induced Peripheral Neuropathy

Minia University

Phase 1/2 Completed
60 enrolled

Hereditary Sensory and Autonomic Neuropathies, Peripheral Nervous System Diseases

NCT04939857 2021-06-25

Effect of Trimetazidine on Radiotherapy-induced Heart Damage.

Peking University Third Hospital

Phase 2/3 Unknown
80 enrolled

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡